Our call to action: be a champion for Phersephone through social media engagement, website visits, product orders, and word-of-mouth referrals to your network.
Persephone Biosciences announced the launch of its groundbreaking Daily Synergistic Synbiotic, addressing a critical health crisis: nine out of ten babies are missing essential Bifidobacterium strains that were once universal in healthy infants. Based on the largest U.S. infant gut microbiome study ever conducted, this breakthrough product combines four keystone bacterial strains with human milk oligosaccharides (HMOs) to restore missing microbes linked to lifelong immune health.
The Persephone synbiotic represents a paradigm shift in infant care, featuring two proprietary Bifidobacterium infantis strains plus supporting species, paired with breast milk sugars proven to fuel bacterial colonization.
The Company's products have been clinically validated in one of the largest infant microbiome trial of its kind and certified by the Clean Label Project, the product addresses the alarming rise in immune-driven conditions like eczema, food allergies, and type 1 diabetes that correlate with modern microbiome depletion.
Available now at Persephone.bio in two formulations—Bloom (infants) and Thrive (toddlers).
Persepone has seen overwhelming market response with over 10,000 parents joining the waitlist in just one month demonstrates urgent demand for this science-backed solution to restore essential gut health in the next generation.
